Search Bar & Filters
Found 604 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating blood biomarkers to classify injury severity and predict neurologic recovery in patients with acute traumatic spinal cord injuries SCI. This observational study at Vancouver General Hospital focuses on patients with cervical and thoracic SCI and aims to validate specific proteins in the blood, understand their serum and plasma relationships, and establish the accuracy of point-of-care devices for these biomarkers. The study also supports the collection of biospecimens for the International Spinal Cord Injury Biobank. Participants include those with traumatic spinal cord injuries and patients with spinal fractures or dislocations without neurologic injury as controls. Blood samples are collected daily for the first week after injury, with follow-up neurologic assessments conducted at 6 and 12 months. The study measures blood levels of Neurofilament Light Chain NF-L and Glial Fibrillary Acidic Protein GFAP, and assesses neurologic function using standard examinations. During the study, participants provide informed consent and have blood drawn through existing arterial, central, or intravenous lines within 24 hours of injury. Researchers monitor biochemical markers in blood during the first week and conduct neurologic evaluations at 6 and 12 months post-injury. The study duration extends until December 2030, with ongoing data collection and biospecimen support to improve understanding of SCI recovery and biomarker accuracy.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating how forming a physical activity PA identity within families can promote long-term physical activity among children aged 6 to 12 years. The study compares an identity formation approach, which includes education and planning plus additional coaching, to a standard education and planning condition. The main goal is to see if children in the identity formation group increase their moderate- to vigorous-intensity physical activity MVPA more over six months. Participants are divided into two groups. One group receives sessions, informational booklets, and worksheets based on Canadas PA guidelines, focusing on how parents can support their childs physical activity through encouragement, logistical help, and doing activities together. This group also receives materials on healthy family eating. The other group receives the same materials plus two extra coaching sessions that include family PA identity activities, such as assigning fun PA roles to family members and creating family PA items like t-shirts and photos, to strengthen social identity related to physical activity. During the six-month study, researchers will monitor childrens MVPA at baseline, 6 weeks, 3 months, and 6 months. Additional assessments include parent-child activity tracking through accelerometers and self-reports, body measurements, cardiovascular and musculoskeletal fitness tests, and social identity questionnaires. The study aims to understand how family support and identity impact childrens physical activity and health outcomes, with the University of Victoria leading the research.
Actively Recruiting
Researchers are evaluating different radiation treatments for men newly diagnosed with low volume oligometastatic prostate cancer, defined as fewer than five bone metastases andor non-regional lymph node involvement. The study aims to compare ultrahypofractionation using stereotactic ablative radiotherapy SABR or brachytherapy with moderately hypofractionated external beam radiotherapy EBRT to see if they are similarly well-tolerated. Secondary goals include assessing progression-free survival, overall survival, and cost-effectiveness. The trial hypothesizes that ultrahypofractionation will provide favorable toxicity profiles and quality of life while maintaining similar or better effectiveness, offering a convenient and cost-effective alternative to standard EBRT. Participants will be randomly assigned to one of four treatment groups standard EBRT delivering 5500 centiGray in 20 fractions over 4 weeks a single outpatient fraction of 19 Gray high dose rate brachytherapy under anesthesia a single outpatient permanent implant of radioactive Iodine-125 seeds delivering 125 Gy under anesthesia or SABR delivering 36.25 Gy in 5 fractions either weekly or every second day. Each treatment center selects its preferred brachytherapy or SABR option to balance enrollment across the four groups. During the study, urinary symptoms will be closely monitored over two years using the International Prostate Symptom Score IPSS at six time points. Additional assessments include quality of life questionnaires focusing on urinary, bowel, and sexual health, as well as biochemical markers, progression monitoring, survival, and cost-effectiveness over up to three years. Participants will complete these evaluations while receiving long-term androgen deprivation therapy and follow-up care to track treatment impact and safety.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of ifinatamab deruxtecan I-DXd, alone or combined with other treatments, in people with metastatic castration-resistant prostate cancer mCRPC. This study aims to understand how well participants tolerate the treatment, find a safe dose level for combination therapies, and monitor prostate-specific antigen PSA levels during treatment. The study is part of a larger master screening protocol and includes participants with advanced prostate cancer. Participants may receive one of several treatment plans docetaxel chemotherapy every three weeks for up to 10 cycles I-DXd alone every three weeks until side effects, disease progression, death, or withdrawal I-DXd combined with opevesostat after dose escalation until stopping criteria are met or I-DXd combined with an androgen receptor pathway inhibitor abiraterone or enzalutamide under similar conditions. Before each I-DXd dose, participants take medications to prevent nausea and vomiting. During the study, participants will have regular assessments including monitoring for treatment side effects, PSA response, and disease progression. Researchers will track dose-limiting toxicities, adverse events, and reasons for stopping treatment over periods ranging from about three weeks to over four years. Secondary measures include overall survival, radiographic progression-free survival, and time to pain progression. Participation may last several years, with ongoing safety and effectiveness evaluations carried out throughout this time.
Actively Recruiting
Researchers are investigating new treatment options for people living with HIV-1, focusing on improving the current standard of care. The study compares a new once-weekly antiretroviral therapy ART combining islatravir and ulonivirine to the standard daily ART regimen, which includes multiple medications taken up to twice a day. This research aims to evaluate if the new study ART works as well as the current standard treatment, while also assessing its safety and how well participants tolerate it. Participants will be randomly assigned to one of several groups one group will receive the study drugs islatravir and ulonivirine once weekly, another will take the standard ART daily, and two additional groups will receive combinations of study drugs and placebos for 96 weeks. The study involves both phase 2 and phase 3 parts, with participants taking their assigned medication orally either once daily or once weekly during this period. Throughout the study, participants will attend regular visits for up to 96 weeks where researchers will monitor their HIV-1 RNA levels, CD4 T-cell counts, body weight, and any adverse events. The main measurement is the percentage of participants with HIV-1 RNA below 50 copiesmL at weeks 24 and 48 for phase 2 and phase 3 respectively. Safety and tolerability will also be closely observed, including any discontinuation due to adverse events. Participants health will be followed through various laboratory tests and assessments during the study period.
Actively Recruiting
Researchers are investigating new treatments for high-risk, early-stage breast cancer, focusing on triple-negative breast cancer TNBC and hormone receptor-low positiveHER2-negative breast cancer. These types are defined by low or absent HER2 protein and hormone receptors. The study aims to evaluate whether adding sacituzumab tirumotecan sac-TMT, a targeted therapy, to pembrolizumab and chemotherapy improves outcomes compared to pembrolizumab plus chemotherapy alone. Participants are randomly assigned to one of two groups. One group receives sac-TMT intravenously every two weeks with pembrolizumab every three weeks for 12 weeks, followed by pembrolizumab combined with carboplatin and paclitaxel for another 12 weeks, surgery, optional radiation, and additional pembrolizumab for up to 28 weeks. The other group receives carboplatin and paclitaxel with pembrolizumab for 6 weeks, followed by pembrolizumab combined with cyclophosphamide and either doxorubicin or epirubicin for up to 12 weeks, surgery, optional radiation, and pembrolizumab for up to 28 weeks. Additional adjuvant treatments may be given to participants with residual disease. During the study, participants undergo assessments including tumor biopsies, surgery, and optional radiation therapy. Researchers monitor outcomes such as the percentage of participants with no detectable cancer at surgery and event-free survival over up to 92 months. Secondary measures include overall survival, quality of life, side effects, and adverse events. The total study duration may extend up to nearly 10 years to monitor long-term effects and safety.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of enicepatide, a dual GLP-1 and GIP receptor agonist, for weight management in adults with obesity or overweight who also have Type 2 diabetes mellitus T2DM. This phase III clinical trial compares multiple doses of enicepatide with a placebo to understand its impact on body weight and diabetes control. Participants will receive once-weekly injections of enicepatide or a placebo using an integrated drug-device combination product. The study has several dosing regimens for enicepatide and includes a placebo group for comparison. Treatment lasts up to 72 weeks, during which participants will receive their assigned injections regularly. Throughout the study, participants will be closely monitored with various assessments including body weight, hemoglobin A1c levels, waist circumference, fasting glucose and insulin levels, cholesterol levels, blood pressure, and quality of life measures. Safety evaluations will also be conducted to track adverse events. The study duration extends through week 72, with multiple outcome measures evaluated from baseline to the end of treatment.
Actively Recruiting
Researchers are evaluating the safety, optimal dose, and effectiveness of a combination treatment involving BNT323 trastuzumab pamirtecan and BNT327 pumitamig in people with advanced breast cancer. This includes patients with hormone receptor-positive or negative, HER2-positive, HER2-low, HER2-ultralow, HER2-null breast cancer, or triple-negative breast cancer. The study is a Phase III, multi-site, open-label trial designed to find the best dose and assess the treatments effects in these groups. The study has two parts. Part 1 involves dose escalation where participants with chemotherapy-pretreated advanced breast cancer receive various dose levels of BNT323 plus BNT327 to determine the recommended Phase 2 dose. Part 2 includes dose optimization and exploratory groups, beginning after Part 1s completion. In Part 2 Cohort 1, participants are randomized into four arms to receive either the combination at the recommended dose, the combination at another dose, BNT323 alone, or BNT327 alone. Other cohorts receive the recommended dose without randomization. Participants will undergo treatment cycles with intravenous infusions of the study drugs and be monitored for safety, side effects, and tumor response for up to 36 months. Assessments include tracking dose-limiting toxicities, adverse events, tumor scans, and response rates. Safety monitoring continues up to 90 days after the last dose. The study aims to provide detailed information on the best dose, safety, and potential benefits of these treatments for advanced breast cancer.
Actively Recruiting
Researchers are studying the safety and effectiveness of a drug called tacabrutideg for people with B-cell malignancies, a type of cancer that affects white blood cells. These cancers include various forms such as chronic lymphocytic leukemia, follicular lymphoma, mantle cell lymphoma, and others. The study aims to find the best dose of tacabrutideg and evaluate how well it works in shrinking or eliminating these cancers. The study has two parts first, a dose escalation phase where different doses of tacabrutideg are tested to find a recommended dose that is safe and tolerable. Then, an expansion phase enrolls more participants to further assess the safety and effectiveness of the selected dose or doses. Tacabrutideg is given orally. The study includes multiple groups of participants with different types of B-cell malignancies, including some specific cohorts like Japanese participants and those who have not previously received certain kinase inhibitors. Participants will visit clinics regularly over about three years for treatment, health checks, blood tests, tumor imaging, and other assessments. Researchers will monitor side effects, measure cancer response, and collect blood samples to study how the drug behaves in the body. The main outcomes include safety, identifying the best dose, and overall cancer response rates. The study is open label, so both participants and doctors know the treatment given.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating how supportive environments, policies, and practices in licensed childcare centers in British Columbia BC can increase physical activity and motor skills among children aged 2.5 to 6 years. The study builds on provincial Active Play Standards and the Appetite to Play program, aiming to assess the impact of an enhanced intervention called Appetite to Play that supports childcare providers in sustaining active play best practices. The Appetite to Play intervention includes advanced training for childcare managers and staff through workshops and e-learning modules focused on physical literacy, fundamental movement skills, and creating supportive environments for active play and healthy eating. Childcare centers participating in the study are randomized to either receive this intervention immediately or after a 3-month waitlist period, with the control group having access to standard Appetite to Play materials. Participants, including childcare managers, staff, and children, will be involved in baseline and follow-up assessments up to 6 months post-intervention. Researchers will measure changes in active play practices at childcare centers and childrens motor skill development, along with characteristics of childcare settings and providers. The study includes questionnaires, observations, and data collection at multiple time points to monitor adherence and outcomes throughout the trial.
1-10 of 604
1